Autolus Therapeutics plc Aktie News

Autolus announces the publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025.

I remain bullish on Autolus Therapeutics as they advance their CAR T-cell therapy, obe-cel, in a competitive leukemia market. Obe-cel shows durable benefits, with 38% of responders at 33 months needing no further therapy, suggesting potential as a definitive treatment. Recent EU approval and expansion into new indications like non-Hodgkin lymphoma and autoimmune diseases strengthen AUTL's marke...

Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Amanda Cray - Corporate Participant Christian Martin Itin - CEO & Director Robert F. Dolski - Senior VP, CFO & Principal Accounting Officer Conference Call Participants Asthika Sarith Goonewardene - Truist Securities, Inc., Research Division Dingding Shi - Jefferies LLC, Rese...

Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025 Company recently received conditional marketing authorization from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and conditional European marketing authorization from the European Commission (EC) for AUCATZYL® Follow up data from the FELIX trial demonstrating obe-c...

LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 1...

Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows positive CHMP opinion, MHRA conditional marketing authorization and FDA approval LONDON and GAITHERSBURG, Md., July 21, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commer...

LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 3...

Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up More than half of patients still in remission at 24 months 38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel LONDON, June 12, 2025 (GLOBE NEWSWIRE) --...